抗人血小板膜糖蛋白Ⅲa单克隆抗体抑制兔血栓形成的实验研究

The experimental research of inhibitory potency to rabbit thrombosis by McAb against human platelet membren glycoprotein Ⅲa

目的 评价抗人血小板膜糖蛋白Ⅲa单克隆抗体SZ2 1抑制兔血栓形成的能力。方法不同浓度的SZ2 1( 0、10及 2 0 μg/ml)分别加入兔富血小板血浆 (PRP)中 ,进行二磷酸腺苷 (ADP)诱导的兔血小板聚集试验 ;体内注射SZ2 1( 1 5mg/kg) ,注射前及注射后 5、30及 6 0分钟时制备兔PRP ,分别进行聚集试验 ;用颈动静脉旁路血栓模型研究SZ2 1对兔血栓形成的作用 ,2 0只新西兰兔随机分成 4组 ,体内注射SZ2 1,剂量为A组 0 1mg/kg ,B组 0 4mg/kg ,C组 0 75mg/kg ,D为对照组 (SZ391mg/kg) ,然后测定血栓重量。 结果 体外 2 0 μg/ml的SZ2 1对兔血小板抑制率为 80 % ;SZ2 1体内注射 6 0分钟时完全抑制血小板聚集功能 ;血栓模型分组试验 ,各组平均栓重为A组 31mg ,B组 2 1mg ,C组 2 0 2mg ,D组 31mg ,B、C组与对照组间有明显统计学差异 (P <0 0 1)。 结论 单克隆抗体SZ2

Objective To evaluate the inhibitory potency of McAb SZ21 to thrombosis of rabbits.Methods SZ21 was added of rabbit PRP at the final concentration of 0,10 and 20μg/ml.Aggregation test was induced by ADP;PRP was prepared before,and at 5,30 and 60min after infusion of SZ21(1 5mg/kg),then aggregation was tested.We evaluated the inhibitory potency of SZ21 to thrombosis of rabbits by the aid of A V shunt thrombosis model.20 rabbits were divided into A,B,C and D groups randomly.The dose of SZ21 were:A, 0 1mg/kg;B,0 4mg/kg and C,0 75mg/kg,respectively.Group D was used as control (SZ39 1mg/kg).The thrombus was weighed.Results The inhibition rate of ADP (10μM) induced platelet aggregation was 80% at 20μg/ml of SZ21 in vitro,and it could reach 100% if SZ21 was infused in vivo at 1 5mg/kg after 1 hour.The thrombus weights of group B and C were significantly decreased compared with control ( P< 0 01).Conclusion It is possible to inhibit platelet function by ex vivo or in vivo management with McAb SZ21.